Nektar Therapeutics shares declined 13.62 percent on nearly 10 times the average daily volume Monday. Analysts at Jefferies Group have downgraded the company from a buy rating to a hold.
Going forward ... (see research report)
Copyright ® 2016. The Bedford Report. All Rights Reserved.